• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TP53 进化作用评分可识别与头颈癌患者生存率降低和远处转移增加相关的高危突变。

Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer.

机构信息

Department of Otolaryngology Head and Neck Surgery, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.

Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.

出版信息

Cancer Res. 2015 Apr 1;75(7):1527-36. doi: 10.1158/0008-5472.CAN-14-2735. Epub 2015 Jan 29.

DOI:10.1158/0008-5472.CAN-14-2735
PMID:25634208
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4383697/
Abstract

TP53 is the most frequently altered gene in head and neck squamous cell carcinoma, with mutations occurring in over two-thirds of cases, but the prognostic significance of these mutations remains elusive. In the current study, we evaluated a novel computational approach termed evolutionary action (EAp53) to stratify patients with tumors harboring TP53 mutations as high or low risk, and validated this system in both in vivo and in vitro models. Patients with high-risk TP53 mutations had the poorest survival outcomes and the shortest time to the development of distant metastases. Tumor cells expressing high-risk TP53 mutations were more invasive and tumorigenic and they exhibited a higher incidence of lung metastases. We also documented an association between the presence of high-risk mutations and decreased expression of TP53 target genes, highlighting key cellular pathways that are likely to be dysregulated by this subset of p53 mutations that confer particularly aggressive tumor behavior. Overall, our work validated EAp53 as a novel computational tool that may be useful in clinical prognosis of tumors harboring p53 mutations.

摘要

TP53 是头颈部鳞状细胞癌中最常发生改变的基因,超过三分之二的病例存在突变,但这些突变的预后意义仍不清楚。在本研究中,我们评估了一种称为进化作用(EAp53)的新型计算方法,以将携带 TP53 突变的肿瘤患者分为高风险或低风险,并在体内和体外模型中验证了该系统。具有高风险 TP53 突变的患者的生存结局最差,远处转移的发生时间最短。表达高风险 TP53 突变的肿瘤细胞更具侵袭性和致瘤性,并且肺转移的发生率更高。我们还记录了高风险突变的存在与 TP53 靶基因表达降低之间的关联,突出了可能被这组赋予特别侵袭性肿瘤行为的 p53 突变所失调的关键细胞途径。总的来说,我们的工作验证了 EAp53 作为一种新的计算工具,可能对携带 p53 突变的肿瘤的临床预后有用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/383a/4383697/112071030095/nihms658404f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/383a/4383697/87f0b4a3e395/nihms658404f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/383a/4383697/c5319ff01735/nihms658404f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/383a/4383697/052161535db5/nihms658404f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/383a/4383697/a9adb81fed17/nihms658404f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/383a/4383697/112071030095/nihms658404f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/383a/4383697/87f0b4a3e395/nihms658404f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/383a/4383697/c5319ff01735/nihms658404f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/383a/4383697/052161535db5/nihms658404f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/383a/4383697/a9adb81fed17/nihms658404f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/383a/4383697/112071030095/nihms658404f5.jpg

相似文献

1
Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer.TP53 进化作用评分可识别与头颈癌患者生存率降低和远处转移增加相关的高危突变。
Cancer Res. 2015 Apr 1;75(7):1527-36. doi: 10.1158/0008-5472.CAN-14-2735. Epub 2015 Jan 29.
2
TP53 mutations and survival in squamous-cell carcinoma of the head and neck.头颈部鳞状细胞癌中的TP53突变与生存情况
N Engl J Med. 2007 Dec 20;357(25):2552-61. doi: 10.1056/NEJMoa073770.
3
Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients.TP53 编码变异的进化作用评分可预测头颈部癌症患者对铂类药物的反应。
Cancer Res. 2015 Apr 1;75(7):1205-15. doi: 10.1158/0008-5472.CAN-14-2729. Epub 2015 Feb 17.
4
Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neck.SESN1、UHRF1BP1 和 miR-377-3p 的表达作为突变型 TP53 头颈部鳞状细胞癌的预后标志物。
Cancer Biol Ther. 2017 Oct 3;18(10):775-782. doi: 10.1080/15384047.2017.1373212. Epub 2017 Sep 8.
5
The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer.人乳头瘤病毒(HPV)RNA转录、免疫反应相关基因表达及TP53突变在头颈癌诊断和预后分析中的作用
Int J Cancer. 2015 Dec 15;137(12):2846-57. doi: 10.1002/ijc.29649. Epub 2015 Jul 6.
6
The tumor suppressor capability of p53 is dependent on non-muscle myosin IIA function in head and neck cancer.在头颈癌中,p53的肿瘤抑制能力依赖于非肌肉肌球蛋白IIA的功能。
Oncotarget. 2017 Apr 4;8(14):22991-23007. doi: 10.18632/oncotarget.14967.
7
Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients.TP53 突变相关 microRNAs 的表达预测头颈部鳞状细胞癌患者的临床结局。
Ann Oncol. 2013 Dec;24(12):3082-8. doi: 10.1093/annonc/mdt380. Epub 2013 Oct 9.
8
A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma.TP53 突变模型可预测头颈部鳞状细胞癌的预后和治疗反应。
BMC Cancer. 2021 Sep 16;21(1):1035. doi: 10.1186/s12885-021-08765-w.
9
Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma.截断型 TP53 突变对头颈部鳞状细胞癌的预后意义。
Clin Cancer Res. 2011 Jun 1;17(11):3733-41. doi: 10.1158/1078-0432.CCR-11-0183. Epub 2011 Apr 5.
10
A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status.一种新的核因子-κB基因特征在头颈部鳞状细胞癌中与TP53状态相关地差异表达。
Clin Cancer Res. 2007 Oct 1;13(19):5680-91. doi: 10.1158/1078-0432.CCR-07-0670.

引用本文的文献

1
Nrf2 hyperactivation as a driver of radiotherapy resistance and suppressed anti-tumor immunity in head and neck squamous cell carcinoma.Nrf2过度激活作为头颈部鳞状细胞癌放疗抵抗和抗肿瘤免疫抑制的驱动因素。
Clin Cancer Res. 2025 Jul 31. doi: 10.1158/1078-0432.CCR-25-0112.
2
Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes.复发/转移性头颈部鳞状细胞癌的突变图谱及其与免疫检查点抑制剂疗效的关联
Clin Cancer Res. 2025 May 15;31(10):1931-1942. doi: 10.1158/1078-0432.CCR-24-2198.
3
TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.

本文引用的文献

1
A formal perturbation equation between genotype and phenotype determines the Evolutionary Action of protein-coding variations on fitness.基因型与表型之间的一个形式化微扰方程决定了蛋白质编码变异对适合度的进化作用。
Genome Res. 2014 Dec;24(12):2050-8. doi: 10.1101/gr.176214.114. Epub 2014 Sep 12.
2
Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss.头颈部癌的多层基因组分析将TP53突变与3p缺失联系起来。
Nat Genet. 2014 Sep;46(9):939-43. doi: 10.1038/ng.3051. Epub 2014 Aug 3.
3
Prediction and experimental validation of enzyme substrate specificity in protein structures.
TP53 突变的髓系肿瘤:2024 年诊断、风险分层及管理更新
Am J Hematol. 2025 Jun;100 Suppl 4(Suppl 4):88-115. doi: 10.1002/ajh.27655. Epub 2025 Mar 11.
4
Multiple Mutations-A Genetic Marker for Extracapsular Spread in Human Papillomavirus/p16-Positive Oropharyngeal Carcinoma.多重突变——人乳头瘤病毒/p16阳性口咽癌包膜外扩散的遗传标志物
Laryngoscope Investig Otolaryngol. 2025 Feb 4;10(1):e70094. doi: 10.1002/lio2.70094. eCollection 2025 Feb.
5
Are TP53 mutations all alike?TP53基因的突变都一样吗?
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):321-325. doi: 10.1182/hematology.2024000556.
6
Unveiling therapeutic avenues targeting xCT in head and neck cancer.揭示头颈部癌中靶向xCT的治疗途径。
Cell Oncol (Dordr). 2024 Dec;47(6):2019-2030. doi: 10.1007/s13402-024-00997-9. Epub 2024 Oct 3.
7
Continued decitabine/all-trans retinoic acid treatment: extended complete remission in an elderly AML patient with multi-hit TP53 lesions and complex-monosomal karyotype.持续地西他滨/全反式维甲酸治疗:伴有多打击 TP53 病变和复杂单体核型的老年 AML 患者获得延长的完全缓解。
Clin Epigenetics. 2024 Sep 11;16(1):126. doi: 10.1186/s13148-024-01737-4.
8
Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma.头颈部鳞状细胞癌中纳武利尤单抗反应的临床、基因组和免疫微环境决定因素。
Front Immunol. 2024 Jul 29;15:1390873. doi: 10.3389/fimmu.2024.1390873. eCollection 2024.
9
Moving from conventional to adaptive risk stratification for oropharyngeal cancer.从传统风险分层转向口咽癌的适应性风险分层。
Front Oncol. 2024 Mar 14;14:1287010. doi: 10.3389/fonc.2024.1287010. eCollection 2024.
10
LFSPROShiny: An Interactive R/Shiny App for Prediction and Visualization of Cancer Risks in Families With Deleterious Germline Mutations.LFSPROShiny:一个用于预测和可视化具有有害种系突变的家族中癌症风险的交互式 R/Shiny 应用程序。
JCO Clin Cancer Inform. 2024 Feb;8:e2300167. doi: 10.1200/CCI.23.00167.
预测和实验验证蛋白质结构中的酶底物特异性。
Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):E4195-202. doi: 10.1073/pnas.1305162110. Epub 2013 Oct 21.
4
Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells.丝氨酸取代 TP53 密码子 151 上的脯氨酸赋予功能获得活性,导致头颈部癌细胞对失巢凋亡的抵抗和肿瘤进展。
Laryngoscope. 2013 Jun;123(6):1416-23. doi: 10.1002/lary.23846. Epub 2013 Apr 26.
5
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers.口腔鳞状细胞癌的综合基因组特征分析确定了常见的体细胞驱动因素。
Cancer Discov. 2013 Jul;3(7):770-81. doi: 10.1158/2159-8290.CD-12-0537. Epub 2013 Apr 25.
6
p53 mutations in cancer.癌症中的 p53 突变。
Nat Cell Biol. 2013 Jan;15(1):2-8. doi: 10.1038/ncb2641.
7
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.组装和初步鉴定来自不同头颈部肿瘤部位的 85 个基因组验证细胞系的面板。
Clin Cancer Res. 2011 Dec 1;17(23):7248-64. doi: 10.1158/1078-0432.CCR-11-0690. Epub 2011 Aug 25.
8
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.头颈部鳞状细胞癌外显子组测序揭示 NOTCH1 中的失活突变。
Science. 2011 Aug 26;333(6046):1154-7. doi: 10.1126/science.1206923. Epub 2011 Jul 28.
9
The mutational landscape of head and neck squamous cell carcinoma.头颈部鳞状细胞癌的突变全景。
Science. 2011 Aug 26;333(6046):1157-60. doi: 10.1126/science.1208130. Epub 2011 Jul 28.
10
Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma.截断型 TP53 突变对头颈部鳞状细胞癌的预后意义。
Clin Cancer Res. 2011 Jun 1;17(11):3733-41. doi: 10.1158/1078-0432.CCR-11-0183. Epub 2011 Apr 5.